Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing
News Feb 12, 2014
Genisphere LLC has reported that it has been granted a US patent for a novel strand-specific library preparation method for next generation sequencing based on its proven RNA amplification technology.
The new patented process enables amplification and library preparation from clinically relevant RNA samples, adapts easily to a variety of sequencing instruments and systems, and reduces the time required for sample preparation by eliminating labor intensive steps.
Genisphere's RNA amplification technology employs a robust whole-transcriptome amplification process that has been successfully integrated into several assay systems. In 2008, Genisphere's amplification technology was incorporated into the Pathwork Diagnostics Tissue of Origin Test (now offered by Response Genetics), which was cleared by the FDA in 2010. In 2011, the latest version of the company's amplification technology, trademarked Sensation®, was licensed to Affymetrix for microarray applications.
"Genisphere's technology for whole transcriptome amplification is a dynamic commonality among our diverse corporate initiatives, which include targeted therapeutics, clinical diagnostics, and life science", said Bob Getts, Genisphere's Chief Science Officer. "We are pleased to offer these methods to our collaborators and partners who are interested in broadening their translational research initiatives in the areas of new drug discovery, diagnostic assay development, and moving next generation sequencing from the research lab to the clinic. We also see this as an excellent tool to complement our 3DNA nanoparticle technology used for targeted drug delivery since it will help to uncover those molecules that will be ideal targets for companion diagnostics based on next generation sequencing."
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018